efavirenz has been researched along with Obesity in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H | 1 |
| Asif, S; Baxevanidi, E; Chandiwana, N; Fairlie, L; Hill, A; Masenya, M; Serenata, C; Sokhela, S; Venter, WDF | 1 |
| Amberbir, A; Garone, D; Kalima, K; Kandionamaso, C; Kawalazira, G; Kwekwesa, A; Mataka, Y; Matengeni, A; Mateyu, G; Msonko, J; Singano, V; van Lettow, M; van Oosterhout, JJ | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Gasa, L; Giralt, M; Maroto, AF; Mateo, GM; Morón-Ros, S; Moure, R; Quesada-López, T; Villarroya, F; Villarroya, J | 1 |
| Blackhurst, D; De Boever, P; Everson, F; Genis, A; Goswami, N; Lochner, A; Ogundipe, T; Strijdom, H | 1 |
| Bukusi, EA; Cohen, CR; Jakait, B; Onono, M; Patel, RC; Thomas, K; Wools-Kaloustian, KK; Yiannoutsos, C | 1 |
| Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M | 1 |
| Ammassari, A; Battegay, M; Bonora, S; Burger, D; Chêne, G; Dauchy, FA; Fehr, J; Ghosn, J; Gianotti, N; Gogos, C; Grarup, J; Launay, O; Marzolini, C; Mocroft, A; Mussini, C; Obel, N; Raffi, F; Roca, B; Sabin, C; Siccardi, M; Torti, C; Zangerle, R | 1 |
| Grome, H; Jenkins, CA; Kalams, SA; Koethe, JR; Sterling, TR | 1 |
| Back, D; Battegay, M; de Roche, M; Livio, F; Marzolini, C; Siccardi, M; Stoeckle, M | 1 |
1 review(s) available for efavirenz and Obesity
| Article | Year |
|---|---|
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir dis
Topics: Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Obesity; Oxazines; Piperazines; Pregnancy; Pregnancy Outcome; Pyridones; Tenofovir | 2021 |
1 trial(s) available for efavirenz and Obesity
| Article | Year |
|---|---|
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain | 2019 |
8 other study(ies) available for efavirenz and Obesity
| Article | Year |
|---|---|
Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Topics: Adult; Alkynes; Benzoxazines; Body Mass Index; Carbamazepine; Clarithromycin; Computer Simulation; Contraceptives, Oral, Combined; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Humans; Itraconazole; Levonorgestrel; Models, Biological; Obesity; Rifampin; Sex Hormone-Binding Globulin | 2021 |
The burden of gynecomastia among men on antiretroviral therapy in Zomba, Malawi.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Gynecomastia; HIV Infections; Humans; Malawi; Male; Middle Aged; Nipples; Obesity; Prevalence; Quality of Life; Severity of Illness Index | 2017 |
Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System.
Topics: Adipose Tissue; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Diabetes Mellitus, Type 2; Drug Combinations; Endoplasmic Reticulum Stress; Fibroblast Growth Factors; Hep G2 Cells; HIV Infections; HIV Integrase Inhibitors; Humans; Klotho Proteins; Liver; Lopinavir; Maraviroc; Membrane Proteins; Muscle, Skeletal; Obesity; Oxidative Stress; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Thapsigargin; Tunicamycin | 2018 |
Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats.
Topics: Alkynes; AMP-Activated Protein Kinases; Animals; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Diet, High-Fat; Drug Therapy, Combination; Emtricitabine; Heart; Male; Myocardium; Nitric Oxide Synthase Type III; Obesity; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Reperfusion Injury; Tenofovir | 2018 |
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cohort Studies; Contraceptive Agents; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Kenya; Male; Middle Aged; Nevirapine; Obesity; Overweight; Pregnancy; Pregnancy Rate; Treatment Outcome; Young Adult | 2019 |
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Weight; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2015 |
The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cohort Studies; Cyclopropanes; Emtricitabine; Female; HIV Infections; Humans; Male; Metabolic Diseases; Middle Aged; Obesity; Risk Assessment; Tenofovir | 2016 |
Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing.
Topics: Alkynes; Benzoxazines; Body Mass Index; Computer Simulation; Cyclopropanes; Drug Dosage Calculations; Drug Monitoring; HIV; HIV Infections; Humans; Male; Middle Aged; Obesity; Reverse Transcriptase Inhibitors; Risk Factors; RNA, Viral; Viral Load | 2012 |